⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138244 | 0.64 | — | — | |
| SCHEMBL14793665 | 0.57 | — | — | |
| SCHEMBL5604658 | 0.54 | — | — | |
| SCHEMBL16496896 | 0.51 | — | — | |
| SCHEMBL6315578 | 0.49 | — | — | |
| SCHEMBL13499904 | 0.48 | HSP90AA1 (0.38) | — | |
| SCHEMBL3122121 | 0.48 | APP (0.72) | — | |
| SCHEMBL16389228 | 0.48 | APP (0.41) | — | |
| SCHEMBL821688 | 0.46 | LMNA (0.33) | — | |
| SCHEMBL22270434 | 0.46 | ADRA2A (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020161209-A1 | Compositions inducing cleavage of RNA motifs | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-31 | — | — | US | claimed |
| JP-2002510207-A | — | — | 2002-04-02 | — | — | JP | claimed |
| EP-0866865-B1 | CHIMERIC OLIGOMERS HAVING AN RNA-CLEAVAGE ACTIVITY | VIMRX HOLDINGS LTD (US) | 2002-02-06 | — | — | EP | claimed |
| US-6300483-B1 | FORM, IN COMBINATION WITH AN RNA SUBSTRATE, A STRUCTURE RESEMBLING A HAMMERHEAD STRUCTURE; ANTISENSE THERAPY | RIBOZYME PHARMACEUTICALS, INC. | 2001-10-09 | — | — | US | claimed |
| EP-1019497-A1 | HAMMERHEAD RIBOZYMES WITH EXTENDED CLEAVAGE RULE | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-07-19 | — | — | EP | claimed |
| JP-2000501284-A | — | — | 2000-02-08 | — | — | JP | claimed |
| US-6015886-A | ANTISENSE AGENTS WITH MODIFICATIONS INCLUDING P-ALKOXY AND 2'-O-METHYL GROUPS; NUCLEASE RESISTANT, ABILITY TO ACTIVATE BACTERIAL RIBONUCLEASE H, FORM STABLE DUPLEXES WITH RNA, AND HAVE STRONG HYDROPHOBICITY FOR EFFICIENT CELLULAR UPTAKE | CHEMGENES CORPORATION (US) | 2000-01-18 | — | — | US | claimed |
| WO-1998058057-A9 | COMPOSITIONS INDUCING CLEAVAGE OF RNA MOTIFS | INNOVIR LAB INC (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1998058057-A1 | COMPOSITIONS INDUCING CLEAVAGE OF RNA MOTIFS | INNOVIR LABORATORIES, INC. (US) | 1998-12-23 | — | — | WO | claimed |
| WO-1998058058-A1 | HAMMERHEAD RIBOZYMES WITH EXTENDED CLEAVAGE RULE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-12-23 | — | — | WO | claimed |
| EP-0866865-A1 | CHIMERIC OLIGOMERS HAVING AN RNA-CLEAVAGE ACTIVITY | Vimrx Holdings, Ltd. (US) | 1998-09-30 | — | — | EP | claimed |
| WO-1997018312-A9 | CHIMERIC OLIGOMERS HAVING AN RNA-CLEAVAGE ACTIVITY | — | 1998-08-13 | — | — | WO | claimed |
| WO-1997018312-A1 | CHIMERIC OLIGOMERS HAVING AN RNA-CLEAVAGE ACTIVITY | VIMRX HOLDINGS, LTD. (US) | 1997-05-22 | — | — | WO | claimed |
| US-11814407-B2 | Multiple coupling and oxidation method | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20020161209-A1 | Compositions inducing cleavage of RNA motifs | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6441158-B1 | OLIGOPEPTIDE | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. | 2002-08-27 | — | — | US | disclosed |
| WO-1999033971-A1 | OLIGOMERS THAT BIND TO KU PROTEIN | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1998058057-A9 | COMPOSITIONS INDUCING CLEAVAGE OF RNA MOTIFS | INNOVIR LAB INC (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1998058057-A1 | COMPOSITIONS INDUCING CLEAVAGE OF RNA MOTIFS | INNOVIR LABORATORIES, INC. (US) | 1998-12-23 | — | — | WO | disclosed |
| WO-1998058058-A1 | HAMMERHEAD RIBOZYMES WITH EXTENDED CLEAVAGE RULE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-12-23 | — | — | WO | disclosed |